Back

Efficacy of colchicine in reducing cardiovascular events in patients with low-to-normal LDL-C levels

23 April 2026 (12:30 - 13:15)
Organised by: Logo
Congress Presentation Part of: Heterogeneity of vascular and atherosclerotic risk phenotypes Biomarkers EAPC Premium Access ESC Preventive Cardiology 2026 European Association of Preventive Cardiology (EAPC)

About the speaker

Photo
Mrs Tamar Shengelia

Tbilisi state university clinic VIvamedi, Tbilisi (Georgia)

2 More presentations in this session

Presentation thumbnail
Prognostic impact of total physiologic atherosclerotic burden and residual cholesterol risk in statin-treated patients undergoing PCI
Miss H. Sze (Hong Kong, HK)
Abstract Slides
Presentation thumbnail
Effect of the ugt1a3*2 haplotype on pharmacokinetics and pharmacodynamics of atorvastatin in patients with coronary heart disease
Ms A. Uduma (Oslo, NO)
Abstract Slides

Access the full session

Session thumbnail
Heterogeneity of vascular and atherosclerotic risk phenotypes

The Event

Event poster

ESC Preventive Cardiology 2026

23 April 2026 12:30 CET
You may be interested in
thumbnail
Webinar
Biomarkers of clinical utility in cardiovascular disease
thumbnail
Congress Session
Challenges and innovations in cardiovascular risk stratification with cardiac biomarkers
thumbnail
Webinar
Personalised secondary prevention post-ACS: the role of biomarkers

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources